Prenetics(US:PRE)2025-11-10 12:29Revenue Performance - Total revenue for Q3 2025 reached $23.6 million, a 568% increase year-over-year [13] - IM8's monthly revenue hit a record $9 million in October 2025, representing a 36% month-over-month growth from September [3] - IM8 is projected to achieve $180 to $200 million in revenue for FY 2026, translating to approximately $25 million in monthly revenue or $300 million ARR by year-end 2026 [20] - Prenetics expects Q4 2025 revenue for IM8 to be $28 million, representing a 63% quarter-over-quarter increase compared to Q3 2025 [19] - Revenue for the nine months ended September 30, 2025, was $55,832,000, a significant increase from $9,374,000 in the same period of 2024, representing a growth of 496% [34] - Revenue for the three months ended September 30, 2025, was $23,555,000, a 33.5% increase from $17,680,000 in the previous quarter and a significant increase from $3,528,000 in the same quarter last year [35] - Revenue from the IM8 business unit reached $17,214,000 for the three months ended September 30, 2025, compared to $9,754,000 in the previous quarter [37] - CircleDNA revenue for the three months ended September 30, 2025, was $2,353,000, up from $2,210,000 in the previous quarter [37] Financial Metrics - The company reported a gross margin of 60% in Q3 2025, with a payback period of 3.9 months, indicating strong unit economics [6] - Adjusted EBITDA loss improved to $(2.1) million in Q3 2025, a 49.6% decrease compared to Q3 2024 [13] - Gross profit for the same period was $14,024,000, compared to $7,289,000 in the previous quarter, reflecting an increase of 92.5% [35] - Loss from operations decreased to $6,164,000 for the three months ended September 30, 2025, down from $10,065,000 in the previous quarter [35] - Adjusted EBITDA for the three months ended September 30, 2025, was $(2,083,000), an improvement from $(4,132,000) in the previous quarter [36] - Loss from operations for the nine months ended September 30, 2025, was $24,591,000, slightly higher than the loss of $23,990,000 in 2024 [34] - Total comprehensive expense for the period was $(7,408,000), a decrease from $(12,406,000) in the previous quarter [35] - The company reported a loss for the period under IFRS of $(8,693,000) for the three months ended September 30, 2025, compared to $(12,727,000) in the previous quarter [36] Assets and Liabilities - Total assets as of September 30, 2025, were $196,507,000, a decrease from $199,106,000 as of June 30, 2025 [33] - Total liabilities decreased to $35,305,000 as of September 30, 2025, from $48,214,000 as of June 30, 2025 [33] - Current assets under IFRS as of September 30, 2025, were $38,276,000, significantly lower than $75,747,000 as of December 31, 2024 [38] Strategic Initiatives - Prenetics maintains approximately $120 million in total liquidity, including $82 million in cash and cash escrow, and zero debt [14] - The company has accumulated 387 BTC valued at approximately $41 million as part of its Bitcoin treasury strategy [15] - Prenetics is conducting a strategic review of non-core assets to focus on its highest-growth business unit, IM8 [17] - Management is focusing on new business strategies in genomics and precision oncology, particularly in early cancer detection [1] - The company completed the divestment of ACT Genomics on October 1, 2025, which is now excluded from continuing operations [28] Shareholder Information - Loss attributable to equity shareholders for the nine months ended September 30, 2025, was $30,208,000, compared to $29,962,000 in 2024 [34] - Basic loss per share for the nine months ended September 30, 2025, was $(2.26), compared to $(2.42) in 2024 [34] Cryptocurrency Holdings - Cryptocurrency assets increased to $28,334,000 as of September 30, 2025, up from $20,285,000 as of June 30, 2025 [33]